4th Quarter - Amendment
INTERNATIONAL MYELOMA FOUNDATION for INTERNATIONAL MYELOMA FOUNDATION
Income
—
Expenses
$23,005
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 23, 2026 | $81,388 | Replaced |
| 4th Quarter - Amendment (this page) | Apr 23, 2026 | $23,005 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Access Issues, Cancer Drug Parity Act, Safe Step Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIELLE DOHENY | — |
Budget/Appropriations BUD
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIELLE DOHENY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.